Top 5 Drug Type | Count |
---|---|
Small molecule drug | 7 |
Chemical drugs | 3 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism gp120 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CDK9 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2024 |
Sponsor / Collaborator Palacky University [+3] |
Start Date13 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
NBD-14204 ( ITIH4 ) | Acute Myeloid Leukemia More | Preclinical |
LGR-3922 ( FLT3 x G6PD x SRC family ) | Adult Acute Myeloblastic Leukemia More | Preclinical |
VFP-B-3 ( PDE4 x PDE7 ) | Autoimmune Diseases More | Preclinical |
CAN508 ( CDK9 ) | Neoplasms More | Preclinical |
FKK6 | Inflammation More | Preclinical |